"When a doctor says you have cancer, you’re hit with a flood of emotions all at once – shock, fear, maybe even anger and a desire to fight back. We understand. At Providence Cancer Services, you will find the treatment and support you need. Our skilled team members will outline your treatment options and connect you with many helpful resources. Knowledge is power. And we’re here to help you power through your cancer journey – and lift you up any way we can."

During the past decade, Providence Regional Cancer System-Lacey conducted 146 clinical trials. In the 10-year time frame, 146 clinical trials started and 61 clinical trials were completed, i.e. on average, 41.8% percent of trials that started reached the finish line to date. In the past 5 years, 59 clinical trials started and 53 clinical trials were completed. i.e. 89.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Providence Regional Cancer System-Lacey" #1 sponsor was "National Cancer Institute (NCI)" with 89 trials, followed by "Alliance for Clinical Trials in Oncology" with 31 trials sponsored, "SWOG Cancer Research Network" with 30 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 16 trials sponsored and "Novartis Pharmaceuticals" with 16 trials sponsored. Other sponsors include 15 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Providence Regional Cancer System-Lacey" #1 collaborator was "National Cancer Institute (NCI)" with 89 trials as a collaborator, "NRG Oncology" with 17 trials as a collaborator, "Canadian Cancer Trials Group" with 8 trials as a collaborator, "Genentech, Inc." with 3 trials as a collaborator and "Millennium Pharmaceuticals, Inc." with 2 trials as a collaborator. Other collaborators include 18 different institutions and companies that were collaborators in the rest 28 trials.

According to Clinical.Site data, the most researched conditions in "Providence Regional Cancer System-Lacey" are "Invasive Breast Carcinoma" (8 trials), "Recurrent Squamous Cell Lung Carcinoma" (8 trials), "Recurrent Ovarian Carcinoma" (6 trials), "Stage IV Lung Cancer AJCC v8" (6 trials) and "Stage IV Squamous Cell Lung Carcinoma AJCC v7" (6 trials). Many other conditions were trialed in "Providence Regional Cancer System-Lacey" in a lesser frequency.

Most popular intervention types in "Providence Regional Cancer System-Lacey" are "Drug" (153 trials), "Other" (108 trials), "Biological" (83 trials), "Procedure" (54 trials) and "Radiation" (26 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (51 trials), "Quality-of-Life Assessment" (46 trials), "Questionnaire Administration" (31 trials), "Biospecimen Collection" (30 trials) and "Computed Tomography" (30 trials). Other intervention names were less common.

The vast majority of trials in "Providence Regional Cancer System-Lacey" are 162 trials for "All" genders, 25 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Providence Regional Cancer System-Lacey". undefined are not yet recruiting, 57 are recruiting, 89 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 32 completed trials in Providence Regional Cancer System-Lacey, 5 suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Providence Regional Cancer System-Lacey, 5 "Phase 1" clinical trials were conducted, 95 "Phase 2" clinical trials and 98 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 4 trials that are defined as “Not Applicable".